A method for assaying a novel phosphodiesterase-4 inhibitor, 2-aryl-7(3 0 ,4 0 -dialkoxyphenyl)-pyrazolo [1,5-alpha] pyrimidine (PDE-310), was developed and validated in rat plasma using liquid chromatography -tandem mass spectrometry (LC -MS-MS). Rat plasma samples were processed by liquid-liquid extraction with ethyl acetate and injected onto the LC-MS-MS system for quantification. PDE-310 and imipramine (i.e., internal standard) were separated using a Gemini C18 column with mixture of acetonitrile and 0.1% formic acid (70:30, v/v) as the mobile phase. The ion transitions monitored were m/z 425.0 ! 331.0 for PDE-310 and m/z 281.3 ! 86.1 for imipramine in the multiple-reaction monitoring mode. The detector response was specific and linear for PDE-310 concentrations in the range of 0.1 -50 mg/mL. The intra-day and inter-day precision and accuracy of the method were determined to be within the acceptance criteria for assay validation guidelines. The recoveries were approximately 85.7 and 88.2% from rat plasma for PDE-310 and imipramine, respectively. PDE-310 was stable under various processing and handling conditions. PDE-310 concentrations were readily measured in rat plasma samples up to 8 h after an intravenous administration of PDE-310, suggesting that the assay is practically useful.
Introduction
Phosphodiesterases (PDEs), enzymes that regulate the intracellular levels of cyclic nucleotide second messengers (i.e., cAMP and cGMP), play a central role in signal transduction and in the regulation of physiologic responses (1) . PDEs exist in various isoforms, which are categorized based on structural similarity (i.e., sequence homology and protein domains) and enzymatic properties (i.e., substrate specificity, kinetic properties and sensitivity to endogenous regulators and inhibitors) (2, 3) . Among the isozymes, PDE type 4 (PDE-4) is a major cytosolic PDE isoform (4) and is present in all inflammatory and immunomodulatory cells (5) . It plays a major role in modulating the activity of these cells (6) and is inhibited by selective PDE-4 inhibitors (7, 8) . Thus, a number of inhibitors of PDE-4 (i.e., roflumilast and cilomilast) have been under development for use in the treatment of asthma and/or chronic obstructive pulmonary disease (COPD) (9) . The use of such inhibitors results in an increase in the intracellular concentrations of cAMP, which has anti-inflammatory effects that are involved in asthma and COPD (10 -12) . In addition, various PDE-4 inhibitors have been considered for use in the treatment of age-related memory impairment (13) , tumor necrosis (14) and hypothalamopituitary-adrenal axis (15) .
2-Aryl-7(3 0 ,4 0 -dialkoxyphenyl)-pyrazolo [1,5-alpha] pyrimidine (PDE-310), a novel PDE-4 inhibitor, was recently synthesized and is under development for the treatment of asthma, COPD, arthritis, atopic dermatitis, tumors and degenerative brain diseases (2) . It has been reported that the compound has an IC 50 value of 0.042 mM for PDE-4 inhibition and an EC 50 value of 1.61 mM for cAMP accumulation in vitro (16) . Furthermore, PDE-310 exhibits anti-asthmatic activity by virtue of its ability to inhibit airway hyper-reactivity and eosinophil infiltration in asthmatic animal models (2) .
In addition, the development of selective and sensitive analytical methods for the quantitation of drugs is critical for pre-clinical and/or clinical biopharmaceutical studies. Liquid chromatography coupled with tandem mass spectrometry (LC -MS-MS) using multiple-reaction monitoring (MRM) offers high selectivity and sensitivity for the determination of drug levels, and has been widely used for assays that are conducted in biological fluids (17) .
Therefore, the purpose of this study was to develop and validate a method for the assay of PDE-310 in rat plasma using LC-MS-MS. Unfortunately, the validation of the determination for PDE-310, a new drug candidate for a PDE-4 inhibitor, in biological fluids has never been reported. In this study, the method was evaluated based on its accuracy, precision, selectivity, sensitivity and reproducibility.
Experimental
Chemicals PDE-310 was synthesized with .99.0% purity by the Medicinal Science Division at the Korea Research institute of Chemical Technology (Daejeon, Korea). Imipramine, an internal standard (IS), was purchased from Sigma-Aldrich (.99 purity; St. Louis, MO). Acetonitrile, methanol and ethyl acetate were purchased from J.T. Baker (Phillipsburg, NJ). Distilled water was obtained from a Milli-Q system (Millipore, Bedford, MA). All other chemicals and solvents were of the highest analytical grade available.
Calibration standard and quality control samples A standard stock solution was prepared in methanol at a concentration of 1 mg/mL. Working standard solutions were obtained by further serial dilution of the standard stock solution with methanol. An IS solution (100 ng/mL) was prepared from an IS stock solution (1 mg/mL) with methanol. All solutions were stored at -208C.
Calibration standards for PDE-310 were obtained by spiking the working standard solution in blank rat plasma at final concentrations of 0.1, 0.3, 1, 10, 40 and 50 mg/mL. Quality control (QC) samples for PDE-310 were also prepared at concentrations of 0.3, 1 and 40 mg/mL in rat plasma.
Instrumentation and chromatographic conditions
An Agilent 1200 series HPLC system, coupled to an API 4000 Q trap mass spectrometer (Applied Biosystems, Foster City, CA) equipped with a turbo electro-spray interface, was used for the LC-MS-MS analysis. The spectrometry was set in the positive-ion mode of MRM.
The optimized voltages of collision energy (CE) were 33.0 and 25.0 V for PDE310 and IS, respectively. The pressure of the curtain, nebulizing (GS1) and heating (GS2) gas were 20.0, 40.0 and 50.0 psi, respectively. The temperature of the source was set at 3508C. The most abundant product ions of compounds were at m/z 331.0 from the parent m/z 425.0 of PDE-310, and m/z 86.1 from the m/z 281.3 of IS. Analyst 1.4 software was used for data collection and to control the instrument.
The separation of PDE-310 and IS from endogenous substances was achieved using a Gemini-NX C18 column (50 mm length Â 2.0 mm internal diameter, 3 mm; Phenomenex, Torrance, CA) using a Gemini guard column (4 mm length Â 3.0 mm internal diameter; Phenomenex, Torrance, CA). The mobile phase was composed of acetonitrile and 0.1% formic acid (70:30, v/v), and was delivered at a flow rate of 0.3 mL/min. The temperatures of the auto-sampler and column oven were 4 and 208C, respectively.
Sample preparation
An aliquot (10 mL) of the IS solution was added to a rat plasma sample (50 mL) in a 1.5 mL microfuge tube. Ethyl acetate (1 mL) was added to the mixture, which was then vortexed for 10 min. After centrifugation at 13,000 rpm for 5 min at 48C, the supernatant was transferred to a fresh tube and evaporated to dryness under a stream of nitrogen on a thermal dryer (Dry Thermo bath MG-2100, Eyela, Tokyo, Japan). The residue was reconstituted by adding 500 mL of acetonitrile, and an aliquot (10 mL) of the mixture was injected onto the LC -MS-MS system.
Validation
Validation of the analytical method for PDE-310 was determined with respect to selectivity, sensitivity, linearity and intraday/inter-day accuracy and precision. To evaluate the selectivity of the method, interference by endogenous compounds was assessed by comparing the ion chromatograms for drug-free plasma, plasma with only PDE-310 added, plasma with only IS added and plasma with both PDE-310 and IS added. For sensitivity of PDE-310, the limit of quantification (LOQ) was determined at the concentration at which the precision was less than 20% of the relative standard deviation (RSD) and the value for the accuracy was between 80 and 120% of the theoretical value (18) . In addition to the RSD-based determination of LOQ, a signal-to-noise ratio was confirmed of no less than 10 for the LOQ sample. The linearity of the assay was assessed using the standard plasma solution containing PDE-310, in the concentration range of 0.1 -50 mg/mL. The sample was processed as described previously and analyzed for the drug and IS. The peak area ratios of PDE-310 to IS were determined and calibration curves were then constructed. A linear regression analysis was conducted to determine the linearity of the calibration curve with a weighing factor (1/x 2 ). The precision and accuracy of the assay were evaluated by analyzing multiple batches of calibration samples. The intra-day and inter-day variations were estimated by analyzing spiked samples at four different concentrations (0.1, 0.3, 1 and 40 mg/mL) in a single day and for five days, respectively. The intra-day and inter-day precision of the method were determined by the RSD at each concentration level. The accuracy was determined by the deviation of the calculated concentrations from theoretical concentrations, the relative error (RE), using the calibration curve.
Recovery and matrix effect
The recovery and matrix effect for PDE-310 were assessed by analyzing three sets of standards at three concentrations (0.3, 1 and 40 mg/mL). The recovery was determined by comparing the peak areas of the analyte spiked before the extraction (Set 1) with those of analyte spiked with the post-extraction matrix (Set 2). The matrix effect was determined by comparing the peak areas of Set 2 with those of reference standards prepared by spiking with the same concentration of PDE-310 in the mobile phase (Set 3). In addition, the process efficiency of the method was calculated by comparing the peak areas of Set 3 with those of Set 1. Each sample set was analyzed in triplicate.
Stability
The stability of PDE-310 was examined for various storage or handling conditions. The study of the stability of PDE-310 in rat plasma included short-term and long-term tests at the QC levels. For the study of short-term stability, freeze-thaw cycle stability, the samples were allowed to stand at room temperature for one day, then at 48C for one day, at -208C for one day, at -808C for one day; to the mobile phase at 48C for one day and one week after preparation, and exposure in the mobile phase at room temperature for one day after preparation. To examine long-term stability, samples were stored at -20 and -808C for 30 days before analysis.
Pharmacokinetic study
Three male Sprague-Dawley rats aged eight weeks old were used for the pharmacokinetic disposition study of PDE-310. The animals were maintained in plastic cages with free access to standard rat diet and water. The room was maintained at a temperature of 23 + 38C, relative humidity of 50 + 10%, with an approximately 12/12-h light/dark cycle. After intravenous administration to the rats at a dose of 10 mg/kg of body weight, blood samples (200 mL) were collected at various times (i.e., 0, 2, 10, 30, 60, 120, 240, 360, 480 and 1440 min) and were immediately centrifuged to obtain plasma samples. The plasma samples were processed as described previously and analyzed to determine the plasma concentrations of PDE-310. The pharmacokinetic parameters were calculated by a standard moment analysis. Thus, the area under the plasma concentration-time curve (AUC t ) was calculated by the linear trapezoidal method from 0 to 24 h. The area under the plasma concentration-time curve from zero to time infinity (AUC 1 ) was calculated as AUC t þ C t /l, where C t is the last measured concentration and l represents the terminal slope of the log-linear portion of the concentration time profile. The terminal half-life (t 1/2 ) was calculated to be 0.693/l. 
Results and Discussion

Mass spectra and chromatography
The product ion mass spectra of PDE-310 and IS were obtained ( Figure 1 ) to determine the primary ion species for each corresponding standard. The most abundant precursor ions
for PDE-310 and IS appeared at m/z 425.0 and 281.3, respectively. The quantification of analytes and IS was performed using the MRM mode. The fragmentation ion at m/z 331.0 was the prominent product ion for PDE-310. Although the fragmentation ion at m/z 58.0 in the mass spectrum of IS was prominent (Figure 1 ), we the ion at m/z 86.1 was selected to determine the concentration of PDE-310 because the precision was better at 86.1 than at 58.0; additionally, its sensitivity was sufficient for determination in this study. Therefore, the IS underwent fragmentation to produce an intense product ion signal at m/z 281.3 ! 86.1. After appropriate adjustment of the chromatographic separation conditions, a reproducible separation of PDE-310, IS and endogenous components was obtained. A chromatogram obtained using a blank plasma sample indicated the absence of any interfering peaks at the retention times for the analyte and IS. Using the analytical conditions developed and standard solutions of PDE-310 and IS, the retention times for PDE-310 and the IS were determined to be approximately 1.24 min and 0.86 min, respectively. The shape of each peak of the drug or IS was symmetrical. Typical peak shape and retention times of MRM chromatograms are shown in Figure 2 . The retention times for PDE-310 and IS in rats after an intravenous administration of the drug were consistent with the values obtained from standard plasma samples, indicating that the specificity of the assay is adequate.
Validation and matrix effect
The MRM chromatograms of double blank plasma, blank plasma and the lower limit of quantification (LLOQ) samples were obtained (Figure 2) . No significant interference was found from the constituents of drug-free rat plasma with the retention time of the analyte or IS. Under the analytical conditions used in this study, the calibration curve for PDE-310 in rat plasma was linear over the PDE-310 concentration range of 0.1 -50 mg/mL. Using a linear least-squares regression analysis of the peak area ratio [i.e., PDE-310 (425.0 ! 331.0) / IS (281.3 ! 86.1)] versus concentration of PDE-310 in plasma, the correlation coefficient (r 2 ) was not less than 0.999, indicating that the LC-MS-MS response is directly proportional to the concentration of PDE-310 in plasma and that the assay is linear.
A summary of the intra-day and inter-day precision and accuracy is shown in Table I . In general, the precision and accuracy were less than 13.4% and within 9.82%, respectively. The intra-day precision in RSD for PDE-310 was less than 8.08%, and the intra-day accuracies were in the range from 1.60 to 8.25%. The inter-day precision in RSD for PDE-310 was less than 13.4%, and the inter-day accuracies were in the range from 1.78 to 9.82%. These results indicate that the precision and accuracy of the current assay are within the recommended values for an assay validation (18) .
A summary of the recovery, matrix effect and process efficiency is shown in Table II . The recoveries of PDE-310 from rat plasma by the current liquid -liquid extraction procedure were determined to be 83.7, 84.1 and 89.4% for concentrations of 0.3, 1 and 40 mg/mL, respectively. The mean matrix effects at the three concentrations were 92.4, 94.2 and 93.5%, respectively, which are acceptable (i.e., less than 20%). Process Table III Stability of PDE-310 in Rat Plasma (n ¼ 5) *Recovery ¼ mean peak area of an analyte added before extraction (Set 1) / mean peak area of an analyte spiked post-extraction (Set 2) Â 100. † Matrix effect ¼ mean peak area of an analyte added post-extraction (Set 2) / mean peak area of the same analyte standards (Set 3) Â 100. ‡ Process efficiency ¼ mean peak area of an analyte added before extraction (Set 1) / mean peak area of the same analyte standards (Set 3) Â 100.
Determination of 2-Aryl-7(3 0 ,4 efficiencies of the current procedure for the three concentrations of PDE-310 were determined to be in the range from 78.1 to 79.4%.
Stability
The stability of PDE-310 was examined for typical storage or handling conditions and the stability of the processed samples (Table III) . In general, the effects of handling or processing conditions on the assay parameters were negligible and were in the range from -10.6 to 5.54% for PDE-310 of the corresponding fresh samples or initial conditions. In the case of short-term and long-term stabilities, the response of the LC-MS-MS system for PDE-310 was comparable to that for the fresh sample, namely -9.81 -4.58% and -12.8 --7.41%, respectively. In the case of post-preparative stability, the samples were found to be stable (i.e., -9.68-5.54%) under a variety of conditions. Therefore, these observations suggest that PDE-310 is reasonably stable under normal storage conditions, processing or sample handling conditions.
Applicability to pharmacokinetic studies
The applicability of the current assay to the pharmacokinetic characterization of PDE-310 involving rat subjects was also examined. Figure 3 shows the temporal profile for PDE-310 concentrations in plasma after a single intravenous administration at a dose of 10 mg/kg of PDE-310. The concentration of the drug was readily measurable in plasma samples collected up to 8 h post-dose. The standard pharmacokinetic parameters such as AUC t , AUC 1 , systemic clearance (CL), volume of distribution (V ss ) and mean residence time (MRT) of PDE-310 were estimated, as shown in Table IV . Therefore, these collective observations suggest that the current assay is readily applicable to pharmacokinetic studies involving the intravenous administration of PDE-310 to rats at a dose of 10 mg/kg.
Conclusions
An LC-MS-MS assay, using the positive-ion mode of MRM, was developed and validated for the determination of PDE-310 in rat plasma. The method was found to be adequate for selectivity, sensitivity, linearity, reproducibility and specificity. In addition, the drug was stable under typical handling/processing conditions. Based on the data reported herein, the assay appears to be applicable for the characterization of the pharmacokinetics of PDE-310 involving the administration of typical doses of the drug. Furthermore, this LC-MS-MS assay validation may be applicable to absorption, distribution, metabolism, excretion and toxicity (ADME/Tox) studies of PDE-310 as a novel phosphodiesterase-4 inhibitor for new drug discovery and development. 
